6 completed. 2 Phase 1, 2 Phase 3, 1 Not applicable, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 2 | Completed 2 |
| Not applicable | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow Agrippal: new trials by email Literature Review of Agrippal trials Research Report on Agrippal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months NBP607-QIV, Agrippal - Influenza | Phase 3 | Completed | SK Bioscience Co., Ltd. | 676 | 2018-10-25 | 2022-05-11 |
| Safety, Tolerability and Immunogenicity of NBP607QIV in Healthy Adult Volunteers NBP607QIV, Agrippal - Influenza | Phase 1 / Phase 2 | Completed | SK Chemicals Co., Ltd. | 100 | 2014-02-17 | 2019-02-01 |
| Immunogenicity of a Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Undergoing Hemodialysis Fluad, Agrippal - Influenza, End Stage Renal Failure | Phase 4 | Completed | Korea University Guro Hospital | 174 | 2013-10-01 | 2016-02-19 |
| Training Study to Characterize Biomarkers to Flu Vaccines Fluad, Agrippal, Placebo - Healthy | Not applicable | Completed | University of Surrey | 49 | 2013-01-01 | 2015-02-16 |
| Safety, Tolerability and Immunogenicity of an Trivalent Inactivated Cell-Culture Influenza Vaccine in Healthy Adults NBP607, Agrippal - Prevention of Influenza | Phase 1 | Completed | SK Chemicals Co., Ltd. | 100 | 2012-09-01 | 2019-03-28 |
| Comparison of the Efficacy of Inflexal V With a Commercially Available Influenza Vaccine in Young Children Inflexal V, Agrippal - Influenza | Phase 3 | Completed | Crucell Holland BV | 1356 | 2009-10-01 | 2014-02-06 |
Influenza, Human (4) · Renal Insufficiency, Chronic (1) · Virus Diseases (1)
SK Chemicals Co., Ltd. (2) · Crucell Holland BV (1) · Korea University Guro Hospital (1) · SK Bioscience Co., Ltd. (1) · University of Surrey (1)
South Korea (2) · China (1) · United Kingdom (1)
David Lewis (1) · Hee Jin Cheong, MD, PhD (1) · Rongcheng Li, MD (1) · Woo Joo Kim, MD, PhD (1) · Woo Joo Kim, Ph.D. (1) · Yun Kyung Kim, MD (1)